Home > Insider Trading > Filing (0000899243-22-028388)

Filing Details

Accession Number:: 0000899243-22-028388
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2022-08-11 16:55:48
Reporting Period:: 2022-08-09

Accepted Time:: 2022-08-11 16:55:48
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1850119	Century Therapeutics Inc.	IPSC	()	DE

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1687880	Versant Venture Capital Vi, L.p.	One Sansome Street Suite 3630 San Francisco CA 94104	No	No	Yes	No
1777652	Versant Ventures Vi Gp-Gp, Llc	One Sansome Street Suite 3630 San Francisco CA 94104	No	No	Yes	No
1777654	Versant Ventures Vi Gp, L.p.	One Sansome Street Suite 3630 San Francisco CA 94104	No	No	Yes	No
1832235	Versant Vantage Ii, L.p.	One Sansome Street Suite 3630 San Francisco CA 94104	No	No	Yes	No
1839789	Versant Vantage Ii Gp-Gp, Llc	One Sansome Street Suite 3630 San Francisco CA 94104	No	No	Yes	No
1839790	Versant Vantage Ii Gp, L.p.	One Sansome Street Suite 3630 San Francisco CA 94104	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2022-08-09	550,000	$13.03	11,816,814	No	4	S	Direct
Common Stock	Disposition	2022-08-09	364,800	$0.00	11,452,014	No	4	J	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct
No	4	J	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	714,095	Indirect	See Footnote

Footnotes

The sale of these shares was effected pursuant to a Rule 10b5-1 trading plan adopted by Versant Venture Capital VI, L.P. ("Versant VI").
The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $13.03 to $13.26, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.
The reportable securities are owned directly by Versant VI. Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant VI, and Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. Each of Versant Ventures VI GP and Versant Ventures VI GP-GP may be deemed to indirectly beneficially own the shares beneficially owned by Versant VI, but disclaim beneficial ownership except to the extent of their pecuniary interest therein.
Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant VI to its limited partners pursuant to a Rule 10b5-1 trading plan.
The reportable securities are owned by Versant Vantage II, L.P. ("Versant Vantage II''). Versant Vantage II GP, L.P. ("Versant Vantage II GP") is the general partner of Versant Vantage II, and Versant Vantage II GP-GP, LLC ("Versant Vantage II GP-GP") is the general partner of Versant Vantage II GP. Each of Versant Vantage II GP and Versant Vantage II GP-GP may be deemed to indirectly beneficially own the shares beneficially owned by Versant Vantage II, but disclaim beneficial ownership except to the extent of their pecuniary interest therein.